Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1)

Next Previous
Search
Trial Profile

A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1)

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ESK-001 (Primary)
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms OPTYK-1
  • Sponsors Alumis

    • Most Recent Events

    • 28 Aug 2024 Status changed from active, no longer recruiting to discontinued.
    • 05 Apr 2024 Status changed from recruiting to active, no longer recruiting.
    • 06 Mar 2024 According to an Alumis media release, the company has secured an upsized $259M Series C financing proceeds from which will be used to support this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top